Description
This Kalorama Information report The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment) focuses on the market for preventing, testing and treating infections in the healthcare environment.
Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Treatment and testing guidelines for the following diseases are covered:
Acinetobacter Baumannii
Clostridium Difficile
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Methicillin-resistant Staphylococcus Aureus (MRSA)
Vancomycin-Intermediate/Resistant Staphylococcus Aureus
Tuberculosis
Urinary Tract Infections
Vancomycin-resistant Enterococcus
Ventilator-Associated Pneumonia
Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections.
Fighting the scourge of HAIs requires a multi-faceted approach. The report will provide a market analysis for each of the three areas:
Prevention (Medical Device/Instrument Sterilization, Wide-Area Sterilization, Other)
Testing Markets for HAI (C.Diff, MRSA, Other)
Treatment Markets
For each segment, the report breaks out the market by major regions (United States, Europe, ROW) and the emerging markets. The infection control market is a stable one for companies involved in these areas. As long as there are infections there will always be a need for controlling these infections. It is a fact that diseases evolve and that new approaches to preventing, diagnosing and treating will be required for the long-term.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies included in this report are:
Advanced Sterilization Products
Becton Dickinson
Belimed AG
bioMerieux
Cantel
Cepheid
Getinge
Kimberly-Clark
Merck & Co.
Nordion
Pfizer
Roche
Sakura Seiki
Steris
TSO3
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARYOverview
- The Nosocomial Infection
Scope and MethodologyTotal Size and Growth of the MarketIssues and Trends Affecting MarketLeading CompetitorsCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDSOverview
- Introduction to Pathogens
- Classification of Antibacterial Organisms
- Patient Risk Factors
- General Infection Statistics
- Populations at Risk for Infection
Demographics of the World
- Life Expectancy
- Nosocomial Infection Statistics
- Common Hospital (nosocomial) Infections
- Description of Infections
Infection Risk Assessments by Hospital Department
- Burn Units
- Intensive Care Units
- Emergency Departments
- Hospital Length of Stay
- Extended Stay Environments
- International Trends in Nursing Facilities
Economic Trends
- Comparison Between Healthcare Spending and Real Health Outcomes
U.S. Government’s National Plan to Prevent Healthcare Associated Infections (HAIs)
- Steering Committee
- The American Recovery and Reinvestment Act of 2009
- Affordable Care Act (ACA) Funding
- Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding
U.S. Statewide Standardized Infection RatioReduction in Hospital Acquired Infections
- Reduction in Infections in Israel
- Burden of Hospital Acquired Infections
- Hospital-Acquired Infection Surveillance Process
Case Studies
- Arizona Prevention Study
- Connecticut Funding for HAI Prevention and Reporting
- Pennsylvania Study of HAI Admissions and Readmissions
Infections and Drug Resistance
- Easing Approvals of Antibiotics
- Causes of Drug Resistance
- Antibiotic Abuse
- Antibiotic Use in Agriculture
- Drug Resistance in Select Populations
- Children
- The Elderly
- Compromised Individuals
- Measures for Reducing Resistance
- Testing for the Selection of Anti-bacterial Therapy
- Monitoring Therapy
- Screening Hospitalized patients
Pharmaceutical Manufacturer and Marketer Trends
- Trends in Partnerships and Alliances
- Developers Trends
CHAPTER THREE: INFECTION PREVENTIONOverview
- Methods of Transmission
- Airborne
- Contact
- Droplet
- Vehicle
- High-Risk Facilities or Departments
- Technology Overview
- Potential Use of Copper for Reducing Infections
- Wide Area Disinfection Methods
- Software for Infection Detection and Control
- Antiseptic-Coated Catheters
- Sterilization vs. Disinfection
- Sterilization
- Disinfection
- Equipment and Solutions
- Heat/Steam Sterilization
- Developments
- Chemical Sterilization
- Sterilants
- Developments
- Radiation Sterilization
- Developments
Market Overview
- Hospital-Acquired Infection Prevention Market by Geographical Region
- Competitive Analysis
CHAPTER FOUR: INFECTION TESTINGOverview
- Drug-Resistance/Susceptibility Testing
- Genotypic Methods
- DNA Sequencing
- Solid-phase Hybridization Techniques
- Microarrays
- Real-time Polymerase Chain Reaction Techniques
- Phenotypic Methods
- Phage-based Assays
- Colorimetric Methods
- The Nitrate Reductase Assay
Specific Serious Hospital-Acquired Infection Testing
- Acinetobacter Baumannii
- Clostridium Difficile
- Developments
- Hospital-Acquired Pneumonia
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Methicillin-resistant Staphylococcus Aureus (MRSA)
- Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
- Developments
- Tuberculosis
- Developments
- Urinary Tract Infections
- Vancomycin-resistant Enterococcus
- Developments
- Ventilator-Associated Pneumonia
New DevelopmentsMarket OverviewTotal Market Size and Forecast
- Hospital-Acquired Infection Testing Market by Geographical Region
Competitive AnalysisCHAPTER FIVE: INFECTION TREATMENTOverviewPrinciples of Anti-bacterial Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmacokinetics
- Monitoring Therapy
Classifications of Antibacterial Products
- Carbapenems
- Cephalosporins
- Macrolides
- Penicillins
- Quinolones
- Sulfonamides
- Tetracyclines
Treatment Guidelines
- Clostridium Difficile
- Gastroenteritis
- Hospital-Acquired Pneumonia
- Ventilator-associated Pneumonia
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Stenotrophomonas maltophilia
- Tuberculosis
- Urinary Tract Infections
Leading ProductsNew DevelopmentsTotal Market Size and ForecastHospital-Acquired Infection Treatment Market by Geographical RegionCompetitive AnalysisCHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL-ACQUIRED INFECTION CONTROLMarket ConsiderationsMarket Overview
- Hospital-Acquired Infection Control Market by Geographical Region
CHAPTER SEVEN: COMPANY PROFILESIntroductionAdvanced Sterilization Products
- Company Performance
Becton, Dickinson
- Company Performance
Belimed
- Company Performance
bioMerieux
- Company Performance
Cantel
- Company Performance
Cepheid
- Company Performance
Getinge Group
- Company Performance
Kimberly-Clark
- Company Performance
Merck & Co
- Company Performance
Nordion
- Company Performance
Pfizer
- Company Performance
Roche
- Company Performance
Sakura SeikiSteris
- Company Performance
Tso3
- Company Performance
LIST OF MAJOR PROVIDERS
